Clinical Trials Browser

Neoplasm Metastasis, Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Neuroectodermal Tumors, Primitive, Peripheral, Desmoplastic Small Round Cell Tumor

Neuroblastoma

Carcinoma, Hepatocellular

Thyroid cancer, Hurthle cell

Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Colonic Neoplasms, Rectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Rhabdomyosarcoma

Liver Neoplasms

Gastrointestinal Stromal Tumors

Carcinoma, Hepatocellular, Neoplasms

Neoplasm Metastasis

Thyroid Diseases, Thyroid Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Locally Advanced Thyroid Gland Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Renal Cell

Carcinoma, Hepatocellular

Breast Neoplasms

Leukemia, Myeloid, Acute

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Brain Neoplasms, Glioblastoma, Glioma, Neurologic Manifestations

Thyroid Carcinoma, Anaplastic

Leukemia, Biphenotypic, Acute

Breast Neoplasms, Breast Neoplasms, Male

Familial medullary thyroid carcinoma, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Carcinoma, Hepatocellular

Carcinoma, Renal Cell, Kidney Neoplasms

Salivary Gland Neoplasms

Carcinoma, Hepatocellular

Prostatic Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Liver Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Neoplasms

Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

Leukemia, Myeloid, Acute

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

PEDS-PLAN

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

NEXIRI2

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

LIVIGNO-1

MOST plus

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

CXD101 in Immunotherapy-related Liver Cancer

OUTREACH2

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis

Combination of Toripalimab and JS004 Therapy for ccRCC

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

GMCAII

SoraGVL

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Sorafenib in Treating Patients With Metastatic Breast Cancer

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

Activity of Sorafenib in Salivary Gland Cancer

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

AflacLL1901 (CHOA-AML)

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)